
FDA Issues Warning to Aurobindo Pharma Subsidiary
The story in brief
Aurobindo Pharma's subsidiary Eugia Pharma Specialities received a U.S. FDA warning letter following prior observations in February and an OAI status in May. Unit I contributes about 2% to the company's revenue. Aurobindo also established a new subsidiary, Auropharm Overseas, for manufacturing and marketing. The company reported ₹9,150 crore revenue for the June quarter and ₹33,653 crore for FY26.